The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

Sponsor
The Affiliated Hospital of Qingdao University
Study ID
NCT04782622
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The combination of Apatinib and Camrelizumab for progressed NSCLC patients with muti-line therapy : a phaseⅠB clinical study. Brief Summary: Immunotherapy has made a major progress in Lung cancer.However, challenges such as primary and acquired resistance, small fraction of benefit population and lack of predictive and prognostic biomarkers even exist. The overall objective response rate is lower than 20% in second line-treatment and the progression-free survival (PFS) is also similar to or poorer than that of conventional second-line chemotherapy. Apatinib is a novel, orally administered, multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FGFR, c-Kit, and other kinases. It functions by inhibiting tumor angiogenesis and proliferative signaling pathways. We would observe and analyze the effectiveness and safety of apatinib combined with Camrelizumab for advanced NSCLC after muti-line therapy to explore the synergistic effect of anti-angiogenic agents and immunotherapy.

Key Dates

Start date
Mar 1, 2021
Status verified
Mar 2021
Primary completion
Jan 1, 2022
Completion
Mar 1, 2023

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Apatinib+Camrelizumab
    treated with apatinib+camrelizumab

Primary Outcome Measure

Objective response rate [ Time Frame: 03.01.2021 to 03.01.2022 ]

Central Contacts

Related Studies